e-learning
resources
Munich 2014
Tuesday, 09.09.2014
ILDs: pathogenesis and clinical features
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors
F. Herrmann, L. Wollin (Biberach, Germany)
Source:
International Congress 2014 – ILDs: pathogenesis and clinical features
Session:
ILDs: pathogenesis and clinical features
Session type:
Poster Discussion
Number:
3501
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Herrmann, L. Wollin (Biberach, Germany). Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors. Eur Respir J 2014; 44: Suppl. 58, 3501
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone
Source: International Congress 2014 – ILDs 1
Year: 2014
Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 4
Year: 2014
Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
The role of CCR2
+
CD4
+
T cells in lung fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital
Source: International Congress 2014 – ILDs 4
Year: 2014
Circulating monocytes from interstitial lung disease patients show an activated phenotype
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Measurement of alveolar nitric oxide in IPF patients and in healthy controls
Source: International Congress 2014 – ILDs 4
Year: 2014
Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment
Source: International Congress 2014 – ILDs 5
Year: 2014
IL-17+ cells immunoexpression in systemic sclerosis pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 6
Year: 2014
Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014
Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014
Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
The role of detection of myositis specific and associated antibodies in Japanese patient with interstitial lung disease
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept